V. Zelman Institute for Medicine and Psychology, Novosibirsk State University, 630090 Novosibirsk, Russia.
International Tomography Center, Siberian Branch of Russian Academy of Sciences, 630090 Novosibirsk, Russia.
Int J Mol Sci. 2023 Apr 14;24(8):7279. doi: 10.3390/ijms24087279.
Cell-free DNA (cfDNA) circulates in the bloodstream packed in membrane-coated structures (such as apoptotic bodies) or bound to proteins. To identify proteins involved in the formation of deoxyribonucleoprotein complexes circulating in the blood, native complexes were isolated using affinity chromatography with immobilized polyclonal anti-histone antibodies from plasma of healthy females (HFs) and breast cancer patients (BCPs). It was found that the nucleoprotein complexes (NPCs) from HF plasma samples contained shorter DNA fragments (~180 bp) than BCP NPCs. However, the share of DNA in the NPCs from cfDNA in blood plasma in HFs and BCPs did not differ significantly, as well as the share of NPC protein from blood plasma total protein. Proteins were separated by SDS-PAGE and identified by MALDI-TOF mass spectrometry. Bioinformatic analysis showed that in the presence of a malignant tumor, the proportion of proteins involved in ion channels, protein binding, transport, and signal transduction increased in the composition of blood-circulating NPCs. Moreover, 58 (35%) proteins are differentially expressed in a number of malignant neoplasms in the NPCs of BCPs. Identified NPC proteins from BCP blood can be recommended for further testing as breast cancer diagnostic/prognostic biomarkers or as being useful in developing gene-targeted therapy approaches.
无细胞 DNA(cfDNA)在血液中循环,被包裹在膜结构(如凋亡小体)或与蛋白质结合。为了鉴定参与血液循环中脱氧核糖核蛋白复合物形成的蛋白质,我们使用固定化多克隆抗组蛋白抗体通过亲和层析从健康女性(HF)和乳腺癌患者(BCP)的血浆中分离天然复合物。结果发现,HF 血浆样品中的核蛋白复合物(NPC)比 BCP NPC 含有更短的 DNA 片段(约 180bp)。然而,HF 和 BCP 血浆中 cfDNA 中 NPC 的 DNA 比例以及 NPC 蛋白与血浆总蛋白的比例没有显著差异。蛋白质通过 SDS-PAGE 分离并通过 MALDI-TOF 质谱鉴定。生物信息学分析表明,在存在恶性肿瘤的情况下,参与离子通道、蛋白质结合、运输和信号转导的蛋白质在血液循环 NPC 组成中的比例增加。此外,在 BCP 中 NPC 中 58 种(35%)蛋白质在多种恶性肿瘤中表达差异。从 BCP 血液中鉴定出的 NPC 蛋白可推荐进一步作为乳腺癌诊断/预后生物标志物进行检测,或作为开发基因靶向治疗方法的有用工具。